Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naive Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

被引：0
|
作者：
Snyder, Jordan [1 ,2 ]
Mansour, Razan [1 ,3 ]
Mammadzadeh, Aytaj [1 ,4 ]
Hashmi, Hamza [1 ,5 ]
Afrough, Aimaz [1 ,6 ]
Alkharabsheh, Omar [1 ,7 ]
Paul, Barry [1 ,8 ]
Atrash, Shebli [1 ,8 ]
Mushtaq, Muhammad Umair [1 ,2 ]
Skikne, Barry S. [1 ,2 ]
Ahmed, Nausheen [1 ,2 ]
Abdallah, Al-Ola [1 ,2 ]
机构：
[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[2] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA
[3] Univ Kansas, Internal Med, Med Ctr, Kansas City, KS USA
[4] Mayo Clin, Div Hematol Oncol, Rochester, MN USA
[5] Med Univ South Carolina, Charleston, SC 29425 USA
[6] Univ Texas Southwestern Med Ctr Dallas, Hematol Malignancies & Cellular Therapy, Dallas, TX 75390 USA
[7] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA
[8] Atrium Hlth, Levine Canc Inst, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187487
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [3] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
  • [4] Comparison of daratumumab-based regimens as second-line therapy in relapsed/ refractory multiple myeloma
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi Lisa
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma M.
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis K.
    Cook, Joselle
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi L.
    Kourelis, Taxiarchis
    Lacy, Martha Q.
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [6] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampos Charalampous
    Utkarsh Goel
    Prashant Kapoor
    Moritz Binder
    Francis K. Buadi
    Joselle Cook
    David Dingli
    Angela Dispenzieri
    Amie L. Fonder
    Morie A. Gertz
    Wilson Gonsalves
    Suzanne R. Hayman
    Miriam A. Hobbs
    Yi L. Hwa
    Taxiarchis Kourelis
    Martha Q. Lacy
    Nelson Leung
    Yi Lin
    Rahma Warsame
    Robert A. Kyle
    S. Vincent Rajkumar
    Shaji K. Kumar
    Blood Cancer Journal, 13
  • [7] Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
    Tan, Chia Jie
    Kacerek, Dylan
    Kampirapawong, Nattawara
    Godara, Amandeep
    Chaiyakunapruk, Nathorn
    CANCER MEDICINE, 2025, 14 (05):
  • [8] Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma
    Wang, Jiasheng
    Arroyo-Suarez, Raul
    Tse, William
    BLOOD, 2021, 138 : 3806 - +
  • [9] Daratumumab-based three drug regimens for high-risk multiple myeloma: A meta-analysis.
    Farooqui, Arafat Ali
    Tariq, Muhammad
    Nabeel, Shaha
    Ashraf, Aqsa
    Ahmed, Zahoor
    Faisal, Muhammad Salman
    Din, Mohammad Ammad Ud
    Shahab, Zartashia
    Setarehaseman, Alireza
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis
    Mohyuddin, Ghulam Rehman
    Sigle, Monia
    Chandrasekar, Viveksandeep Thoguluva
    Aziz, Muhammad
    Abdallah, Al-Ola
    Shune, Leyla
    McClune, Brian
    LEUKEMIA & LYMPHOMA, 2020, 61 (10) : 2519 - 2522
12345